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Oxazaphosphorines (cyclophosphamide (CPA) and ifosfamide (IFO)) represent an
important group of therapeutic molecules due to their substantial antitumor and
immunomodulating activities. Unfortunately, despite the benefits brought by these
molecules, their clinical use shows limitations, notably in chemotherapy, due to the
development of resistance, interpatients variation and toxicities (urinary toxicity,
neurotoxicity and nephrotoxicity). To circumvent these problems, new
oxazaphosphorine analogs have been synthetized and present an interesting anti-
tumor activity alone with reduced toxicity [1]. Pentanoxy moiety has been grafted on
C4 position of ifosfamide (P-IFO). Nevertheless, these new analogs are lipophilic and
unstable in aqueous medium. To administer it, this paper proposes to formulate this
analog into nanocarriers. Lipid nanocapsules form a new generation of nanovector
that can encapsulate a number of anticancer agents [2]. In the present research, P-
IFO-loaded LNCs were formulated and characterized.
A new formulation based on glycerol monooleate (Peceol®) was developed,
optimized and then characterized. Batches of P-IFO-LNCs were obtained with a size
of 47.2±0.7nm with a narrow size distribution and a drug payload of
8.42±1.05mg/g. The suspension remained stable at 4°C for 14 days in terms of
mean particle size, polydispersity index and pH. The drug payload decreased after 7
days but a high rate was still found (5.88±1.01mg/g) up to 14 days. The stealth
properties of these nanoparticles were examined in vitro using the complement
activation (CH50) test. This test revealed a low consumption of plasma protein in
the presence of such P-IFO-LNCs. In vitro cytotoxicity of P-IFO-LNCs was
determined in two human cell lines; i.e. rhabdomyosarcoma (RMS-1) and Ewing
sarcoma (A673) and showed a similar activity compared to the free form. Finally, in
vivo activity testing of P-IFO-LNCs is in progress in a murine model bearing a
RMS-1 xenograft after intravenous administration.
References
[1] Skarbek C, et al., Preactivated Oxazaphosphorines Designed for
Isophosphoramide Mustard Delivery as Bulk Form or Nanoassemblies: Synthesis
and Proof of Concept. Journal of Medicinal Chemistry. 22;58(2):105-17, 2015.
[2] Huynh NT, et al., Lipid nanocapsules: A new platform for nanomedicine.
International Journal of Pharmaceutics. 379(2):201–9, 2009.
Acknowledgments: The authors are very grateful to the Ligue contre le Cancer,
Comité du Maine et Loire and Comité d’Ille et Vilaine which founded this work.
URL de la
notice http://okina.univ-angers.fr/publications/ua15068 [7]
Liens
[1] http://okina.univ-angers.fr/publications?f[author]=24799
[2] http://okina.univ-angers.fr/emilie.roger/publications
[3] http://okina.univ-angers.fr/publications?f[author]=24798
[4] http://okina.univ-angers.fr/n.lautram/publications
[5] http://okina.univ-angers.fr/publications?f[author]=24803
[6] http://okina.univ-angers.fr/j.benoit/publications
[7] http://okina.univ-angers.fr/publications/ua15068
Publié sur Okina (http://okina.univ-angers.fr)
